Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGOVAR: Regorafenib vs Tamoxifen in Ovarian Carcinoma
NCT02584465Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Aug 2015
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in ovarian carcinoma, sponsored by ARCAGY. Started Aug 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
ovarian carcinoma
Beyond the preview
Go deeper on NCT02584465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584465.